Recurrent Community-Acquired Bacterial Meningitis in Adults

Liora ter Horst,1 Matthijs C. Brouwer,1, Arie van der Ende,2,3 and Diederik van de Beek1

1Amsterdam UMC, University of Amsterdam, Department of Neurology, Amsterdam Neuroscience, Meibergdreef, Amsterdam, The Netherlands; 2Amsterdam University Medical Centers, University of Amsterdam, Department of Medical Microbiology and Infection Prevention, Amsterdam Infection and Immunity, Meibergdreef, Amsterdam, The Netherlands; and 3Amsterdam University Medical Centers, University of Amsterdam, Netherlands Reference Laboratory for Bacterial Meningitis, Amsterdam, The Netherlands

**Background.** Recurrent bacterial meningitis has been found to occur in about 5% of meningitis cases.

**Methods.** We analyzed adults with recurrent episodes in a prospective nationwide cohort study of community-acquired bacterial meningitis.

**Results.** Of 2264 episodes of community-acquired bacterial meningitis between 2006 and 2018, 143 (6%) were identified as recurrent episodes in 123 patients. The median age was 57 years (interquartile range [IQR], 43–66), and 57 episodes (46%) occurred in men. The median duration between the first and the current episode was 5 years (IQR, 1–15). For 82 of 123 patients (67%), it was the first recurrent episode, 31 patients had 2–5 previous episodes (25%), 2 had 6–10 episodes (2%), and 2 had >10 episodes (2%). Predisposing factors were identified in 87 of 118 patients (74%) and most commonly consisted of ear or sinus infections (43 of 120, 36%) and cerebrospinal fluid leakage (37 of 116, 32%). The most common pathogens were **Streptococcus pneumoniae** (93 of 143, 65%) and **Haemophilus influenzae** (19 of 143, 13%). The outcome was unfavorable (Glasgow outcome scale score, <5) in 24 episodes with recurrent meningitis (17%) vs 810 for nonrecurrent meningitis patients (39%, $P < .001$). Six of 143 died (4%) vs 362 of 2095 patients (17%, $P < .001$).

**Conclusions.** Recurrent meningitis occurs mainly in patients with ear or sinus infections and cerebrospinal fluid leakage. Predominant causative pathogens are **S. pneumoniae** and **H. influenzae**. The disease course is less severe, resulting in lower case fatality compared with nonrecurrent meningitis patients.

**Keywords.** recurrent meningitis; bacterial meningitis; predisposing factor; vaccination.

Community-acquired bacterial meningitis is a life-threatening infection of the central nervous system [1]. The mortality rate in high-income countries is approximately 20%, and neurological sequelae occur in almost half of the surviving patients [2]. Recurrent episodes of bacterial meningitis have been described in 5% of community-acquired bacterial meningitis cases and have been associated with a relatively favorable prognosis [3]. Several factors have been identified that predispose to recurrent meningitis, such as cerebrospinal fluid (CSF) leakage, remote head injury, and an immunocompromised state [3]. Previous studies have recommended early identification of these predisposing factors to prevent further recurrences [3–6].

The introduction of routine vaccination of children with protein-polysaccharide conjugate vaccines against most common causative pathogens of bacterial meningitis has reduced the incidence of bacterial meningitis and the prevalence of common causative pathogens of meningitis [7, 8]. The 2016 European Society for Clinical Microbiology and Infectious Diseases guideline on community-acquired bacterial meningitis advises to routinely vaccinate patients after community-acquired pneumococcal meningitis (23-valent pneumococcal polysaccharide vaccine [PPV-23], pneumococcal conjugate vaccine [PCV]) as well as those with meningitis and CSF leakage (PPV-23, PCV, **Haemophilus influenzae** type b [Hib], meningococcal serogroup ACWY, and serogroup B vaccines) [9]. However, whether these vaccines are routinely administered and reduce the incidence of recurrent episodes is unclear.

We evaluated patients with recurrent meningitis episodes from a nationwide prospective cohort study to summarize predisposing factors, pathogen distribution, vaccination status, and outcome.

**METHODS**

We prospectively included adult patients with community-acquired bacterial meningitis in the MeninGene study, a nationwide cohort study in the Netherlands, from March 2006 to July
1.

2.

3.

4.

5.

6.

7.

8.

9.

10.

RESULTS

Over the 12-year period, 2264 episodes of community-acquired bacterial meningitis were included. Of these, 143 recurrent episodes (6%) were identified among 123 patients. The median age of these patients during the recurrent episodes included in the study period was 57 years (interquartile range [IQR], 43–66), and 57 (46%) were male. The duration between the first episode and the current episode was known for 116 patients (94%), with a median duration of 5 years (IQR, 2–15). For the majority of patients (82 of 117, 70%), the current episode was the first recurrent episode, and 2 patients (2%) had more than 10 recurrent episodes (Table 1). Potential predisposing factors for bacterial meningitis were identified in 87 of 118 patients (74%; missing in 5 patients); ear or sinus infections (43 of 120, 36%), CSF leakage (37 of 116, 32%), and immunocompromised state (37 of 116, 32%), and immunocompromised state were the most common (17 of 123, 14%). Most common

| Table 1. Characteristics of 128 Recurrent Meningitis Patients |
|---------------------------------------------------------------|
| Characteristic                                               | n/N (%) | Median (IQR) |
| Age, years                                                   | 57 (43–66) |
| Male sex                                                     | 57/123 (46%) |
| Medical history                                              |          |
| Predisposing factors                                         | 87/118 (74%) |
| CSF leakage                                                   | 7/116 (32%) |
| Remote head trauma without sign of CSF leak                  | 4/119 (3%) |
| Immunocompromised state                                      | 17/123 (14%) |
| Extra meningeal foci of infection                             | 44/123 (36%) |
| Otitis media or sinusitis                                     | 43/120 (36%) |
| Pneumonia                                                     | 1/122 (1%) |
| Number of recurrences                                        |          |
| 1                                                            | 82/117 (70%) |
| 2–5                                                          | 31/117 (27%) |
| 6–10                                                         | 2/117 (2%) |
| >10                                                          | 2/117 (2%) |
| Time between first current episode, median (IQR), years       | 5 (2–15) |
| Previous vaccination                                         | 27/92 (29%) |

Abbreviations: CSF, cerebrospinal fluid; IQR, interquartile range.
causes of CSF leakage were ear–nose–throat surgery (10 of 37, 27%) and remote head trauma (9 of 37, 24%). Of the patients with CSF leakage, 15 of 37 (41%) had a recurrent episode despite previous surgical repair. Four of 119 patients (3%) had a history of head trauma without signs of CSF leakage. Predisposing immunocompromising conditions were identified in 17 patients (14%) and included the use of immunosuppressive drugs in 9 (64%), splenectomy in 4 (29%), living with HIV in 2 (14%), and primary immunodeficiencies in 4 patients (29%; complement factor C6 deficiency and mannanning lectin deficiency [n = 1], a C7 deficiency [n = 1], an immunoglobulin [Ig] G-2 deficiency [n = 1], and a late-onset hypogammaglobulinemia [n = 1]). Some patients had more than 1 immunocompromised condition.

Recurrent episodes of bacterial meningitis presented with headache in 121 of 131 episodes (92%), neck stiffness in 94 of 131 (72%), fever in 101 of 137 (74%), and an altered mental status in 65 of 143 (46%; Table 2). Compared with nonrecurrent episodes, the duration of symptoms was more often shorter than 24 hours in recurrent episodes (95 of 142 episodes [67%] vs 912 of 2022 episodes [45%, P < .001]), and fewer episodes presented with an altered mental state (65 of 143 [46%] vs 1480 of 2089 [71%, P < .001]; Table 2).

Brain imaging was performed on presentation and/or during admission in 113 of 143 episodes (76%) and identified abnormalities in 47 of 113 episodes (42%), mainly sinus and/or mastoid opacification (40 of 47 episodes, 85%). Lumbar puncture was performed in all episodes. CSF showed an elevated leukocyte count of more than 1000 cells/mm³ in 104 of 137 episodes (76%), with a median of 3190 cells/mm³ (IQR, 1033–6313). In 117 of 143 episodes (82%), at least 1 independent CSF predictor of bacterial meningitis, according to Spanos, was present in CSF [10].

The causative pathogen was identified in 135 episodes. CSF culture identified the pathogen in 127 of 143 episodes (89%), in 5 episodes (4%) the pathogen was identified by blood culture, in 2 by PCR (2%), and in 1 by both blood culture and PCR (1%). *Streptococcus pneumoniae* was identified in 93 of 135 episodes (69%), *H. influenzae* in 19 of 135 (14%), *Neisseria meningitidis* in 9 of 135 (7%), and *Listeria monocytogenes* in 1 of 135 (1%). Other causative organisms were *Streptococcus agalactiae* (n = 3), *Streptococcus salisarius* (n = 2), *Streptococcus suis* (n = 2), *Streptococcus mitis* (n = 2), *Streptococcus viridans* (n = 2), *Escherichia coli* (n = 1), and *Streptococcus pyogenes* (n = 1). Pneumococcal serotypes were retrieved in 73 of 93 recurrent pneumococcal episodes (78%; Supplementary Table 1) and were most often caused by serotypes 19A (n = 7), 3 (n = 5), 7F (n = 5), 8 (n = 5), 22F (n = 5), and 19F (n = 5). All 19 serotyped *H. influenzae* strains were unencapsulated, of which 2 were β-lactamase–positive and 17 β-lactamase–negative. Meningococcal serogroups were available in 8 of 9 episodes and showed serogroup B in 5 episodes, Y in 2 episodes, and C in 1 episode. Two of 123 patients with recurrent meningococcal meningitis had a known complement deficiency.

Antibiotic treatment consisted of initial empiric therapy with amoxicillin and ceftriaxone according to protocol in 56 of 143 episodes (39%). This initial empiric therapy was adjusted after a pathogen was identified and antibiotic susceptibilities were available to third-generation cephalosporins in 15 of 56 episodes (27%), to penicillin or amoxicillin monotherapy in 33 episodes (59%), to a different regimen in 5 episodes (9%), and was unknown in 1 episode. Whereas in 28 of 143 episodes (36%) monotherapy third-generation cephalosporins were given, 16 (11%) were given penicillin or amoxicillin monotherapy and 19 (13%) were given a different regimen. In 24 episodes, the patients received initial empiric monotherapy third-generation cephalosporins, which was adjusted to penicillin monotherapy. Adjunctive dexamethasone treatment was given in 129 of 142 episodes (91%). Data on prophylactic antibiotics were available for 92 episodes (64%), of which 2 (2%) had a recurrence despite the use of prophylactic antibiotic.

During admission, systemic complications occurred in 43 of 136 episodes (32%). Neurological complications occurred in 48 of 134 episodes (36%; Table 2). The clinical outcome was unfavorable in 24 of 143 episodes (17%), and in 6 of 143 episodes the patient died (4%). The rate of unfavorable outcome was significantly lower compared with nonrecurrent meningitis episodes (810 of 2095, 39%; P < .001). The 4% mortality rate in patients with recurrent meningitis was also significantly lower compared with nonrecurrent cases (362 of 2095, 17%; P < .001). Five patients with recurrent meningitis died after pneumococcal meningitis and 1 after listeria meningitis.

Available vaccines (PPV-23, PCV-13, PCV-7, MenACWY, MenB) could have covered the bacterial strain of 56 of 143 episodes (39%). Vaccination status could be retrieved in 92 of 143 episodes (64%). Of these, 27 were vaccinated (29%): 20 received PPV23, 5 received PCV13, 5 received meningococcal ACWY vaccine, 8 received meningococcal C vaccine, 5 received Hib, 1 received PcV-7, and in 1 episode the type of vaccination was not specified. Vaccination failure occurred in 10 of 26 episodes (39%; Table 3). Eight episodes occurred due to *S. pneumoniae* 7F (n = 2), 19A (n = 2), and 6B, 10A, 19F, and 23F (n = 1) despite adequate PPV-23 vaccination including these serotypes. One meningococcal C and 1 meningococcal Y episode occurred despite meningococcal ACWY vaccination.

After discharge for the current episode, 34 of 143 (24%) received vaccination that consisted of PPV23 in 23 patients, Hib in 12 patients, meningococcal C vaccine in 11, meningococcal ACWY in 2, meningococcal B in 1, and PCV13 and PCV7 both in 2 patients. There was no difference in the proportion of patients with recurrent meningitis prior to or after the guidelines recommended routine vaccination after pneumococcal meningitis (122 of 1858, 7% vs 21 of 406, 5%; P = .37).
Table 2. Recurrent Episodes Compared With Nonrecurrent Episodes

| Characteristic                                      | Recurrent Episodes, No. (%) | Nonrecurrent Episodes, No. (%) | P Value |
|-----------------------------------------------------|----------------------------|--------------------------------|---------|
| Age, median (IQR), years                           | 56 (41–66)                 | 61 (48–70)                     | <.001   |
| Male sex                                            | 67/143 (47%)               | 1093/2121 (52%)                | .30     |
| Medical history                                     |                            |                                |         |
| Previous neurologic deficits                       | 33/139 (24%)               | 200/2081 (10%)                 | <.001   |
| Predisposing factors                                | 103/137 (75%)              | 1113/2028 (55%)                | <.001   |
| CSF leakage                                         | 46/135 (34%)               | 34/2082 (2%)                   | <.001   |
| Remote head trauma without CSF leak                | 4/138 (3%)                 | 52/1985 (3%)                   | .78     |
| Immunocompromised state                            | 19/143 (13%)               | 219/2121 (10%)                 | .26     |
| Extra meningeal foci of infection                   | 51/143 (36%)               | 907/2087 (44%)                 | .08     |
| Otitis media or sinusitis                          | 49/140 (35%)               | 717/2018 (36%)                 | .93     |
| Pneumonia                                           | 2/142 (1%)                 | 197/2012 (10%)                 | <.001   |
| Symptoms at presentation                           |                            |                                |         |
| Symptoms duration <24 hours                        | 95/142 (67%)               | 912/2022 (45%)                 | <.001   |
| Headache                                            | 121/131 (92%)              | 1454/1805 (81%)                | <.001   |
| Neck stiffness                                      | 94/131 (72%)               | 1418/1941 (73%)                | .76     |
| Temperature ≥38°C                                   | 101/137 (74%)              | 1495/2049 (73%)                | .92     |
| Focal neurological deficits                        | 27/143 (19%)               | 739/2100 (35%)                 | <.001   |
| Triad of symptoms                                  | 34/133 (26%)               | 794/1980 (40%)                 | .001    |
| Score on Glasgow coma scale                        |                            |                                |         |
| Median (IQR)                                        | 14 (11–15)                 | 11 (9–14)                      | <.001   |
| ≤14                                                 | 65/143 (46%)               | 1480/2089 (71%)                | <.001   |
| ≤8                                                  | 19/143 (13%)               | 426/2089 (20%)                 | .04     |
| Index of CSF inflammation                          |                            |                                |         |
| Leukocyte count, median (IQR), cells/mm³           | 3190 (1033–6313)           | 2283 (557–6670)                | .14     |
| Protein concentration, g/L                         | 3 (1.7–4.9)                | 3.8 (2.2–6.1)                  | .001    |
| CSF to blood glucose ratio (IQR)                    | 0.22 (0.04–0.37)           | 0.06 (0.012–0.28)              | <.001   |
| CSF pressure                                        | 35 (29–48)                 | 40 (29–50)                     | .15     |
| Blood chemical test result                         |                            |                                |         |
| Erythrocyte sedimentation rate, median (IQR), mm/h | 14 (6–47)                  | 42 (23–70)                     | <.001   |
| C-reactive protein, mg/L                            | 50 (11–134)                | 195 (92–305)                   | <.001   |
| C-reactive protein elevated (>10mg/L)              | 107/143 (75%)              | 1964/2030 (97%)                | <.001   |
| Leukocyte count, ×10⁹/L                             | 16 (12–21)                 | 16 (12–22)                     | .31     |
| Thrombocytes, ×10⁹/L                                | 224 (186–269)              | 197 (147–255)                  | <.001   |
| Causative organism                                  |                            |                                |         |
| Identified by blood culture                         | 85/122 (70%)               | 1341/1819 (74%)                | .33     |
| Identified by CSF culture                           | 127/143 (88%)              | 1888/2121 (89%)                | .94     |
| Streptococcus pneumonia                            | 93/143 (65%)               | 1410/2121 (67%)                | .72     |
| Haemophilus influenzae                             | 19/143 (13%)               | 65/2121 (3%)                   | <.001   |
| Neisseria meningitidis                             | 9/143 (6%)                 | 227/2121 (11%)                 | .12     |
| Listeria monocytogenes                              | 1/143 (1%)                 | 125/2121 (6%)                  | .004    |
| Other organism                                      | 13/143 (9%)                | 198/2121 (9%)                  | 1.00    |
| Negative culture                                    | 8/143 (6%)                 | 96/2121 (5%)                   | .53     |
| Complications during admission                      |                            |                                |         |
| Systemic complications                              | 43/138 (32%)               | 1023/1963 (52%)                | <.001   |
| Respiratory failure                                 | 18/137 (13%)               | 519/2024 (26%)                 | .01     |
| Circulatory shock                                   | 6/137 (4%)                 | 210/1976 (11%)                 | .02     |
| Pneumonia                                           | 8/135 (6%)                 | 317/1953 (16%)                 | .001    |
| Neurologic complications                            | 48/134 (36%)               | 1009/1848 (55%)                | <.001   |
| Focal neurological deficits                         | 36/138 (26%)               | 774/1928 (40%)                 | .001    |
| Cerebrovascular accident                            | 8/140 (6%)                 | 220/1945 (11%)                 | .05     |
| Seizures                                            | 17/140 (12%)               | 280/1996 (14%)                 | .61     |
| Hearing loss                                        | 21/126 (17%)               | 463/1684 (28%)                 | .009    |
| Neurological deficits at discharge                  |                            |                                |         |
| Focal neurological deficits                        | 15/108 (14%)               | 308/1354 (23%)                 | .040    |
| Aphasia                                             | 3/111 (3%)                 | 47/1406 (3%)                   | 1.00    |
| Cranial nerve palsy                                 | 9/111 (8%)                 | 203/1380 (15%)                 | .07     |
| Paresis                                             | 4/107 (4%)                 | 114/1386 (8%)                  | .13     |
| Cognitive impairment                                | 14/111 (13%)               | 279/1380 (20%)                 | .062    |

Downloaded from https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa1623/6159394 by guest on 11 March 2021
Using the NRLBM database, pathogen distribution could be retrieved for 327 episodes, including the current episodes and episodes prior to the current cohort study, among 123 patients (Supplementary Figures 1 and 2A–C). CSF cultures were positive in 245 episodes; *S. pneumoniae* in 167 episodes (68%); *H. influenzae* in 29 (12%); *N. meningitidis* in 29 (12%); *S. agalactiae* and *S. salivarius* in 4 (2%); *S. suis* in 3 (1%); *L. monocytogenes, S. mitis,* and *S. viridans* in 2 (1%); and *Campylobacter species, E. coli,* and *S. pyogenes* all in 1 (0.4%). Twenty-eight of 123 patients (23%) had meningitis episodes caused by 2 different pathogens, 4 patients (3%) had meningitis episodes caused by 3 different pathogens, and 1 patient (1%) had meningitis episodes caused by 4 different pathogens. Six patients had recurrent pneumococcal

| Characteristic | Recurrent Episodes, No. (%) | Nonrecurrent Episodes, No. (%) | P Value |
|----------------|-----------------------------|-------------------------------|---------|
| Score on Glasgow outcome scale a | 6/143 (4%) | 362/2095 (17%) | <.001 |
| 2 | 0/143 (0%) | 6/2095 (0.3%) | 1.00 |
| 3 | 3/143 (2%) | 101/2095 (5%) | 0.15 |
| 4 | 15/143 (11%) | 341/2095 (16%) | 0.08 |
| 5 | 119/143 (83%) | 1285/2095 (61%) | <.001 |

Abbreviation: CSF, cerebrospinal fluid; IQR, interquartile range; N=143 for recurrent episodes of bacterial meningitis; N=2121 for nonrecurrent bacterial meningitis episodes.

* a Focal neurological deficits defined as aphasia or hemiparesis or cranial nerve palsies, including hearing loss.
* b Triad of symptoms = fever, neck stiffness, and change in mental status.
* c Glasgow coma scale: <14 indicates a change in mental status and ≤8 indicates coma.
* d Neurological complications during admission defined as seizures or focal neurological deficits or cerebrovascular accidents or sinus thrombosis.
* e Glasgow outcome scale: 1 indicates death, 2 indicates a vegetative state, 3 indicates severe disability, 4 indicates moderate disability, and 5 indicates mild or no disability.

Table 2. Vaccination Status and Cause of Recurrent Meningitis

| Patient | Type of Vaccination Received | Pathogen | Vaccination Failure |
|---------|------------------------------|----------|---------------------|
| 1       | PPV-23, Men-C, Hib           | *S. pneumoniae* 6B | Yes |
| 2       | PPV-23                       | *S. pneumoniae* 7F | Yes |
| 3       | PPV-23, Men-C, Hib           | *S. pneumoniae* 7F | Yes |
| 4       | PPV-23, Men-C                | *S. pneumoniae* 10A | Yes |
| 5       | PPV-23, Men-C                | *S. pneumoniae* 19A | Yes |
| 6       | PPV-23, Men-C                | *S. pneumoniae* 19A | Yes |
| 7       | PPV-23, PCV-13, Men-ACWY     | *S. pneumoniae*19F | Yes |
| 8       | PPV-23, PCV-13, Men-ACWY     | *S. pneumoniae* 23B | No |
| 9       | PPV-23, Men-C                | *S. pneumoniae* 23F | Yes |
| 10      | PPV-23                       | *S. pneumoniae* 24F | No |
| 11      | PPV-23                       | *S. pneumoniae* 27 | No |
| 12      | PPV-23                       | *S. pneumoniae* 27 | No |
| 13      | missing                      | *S. pneumoniae* a | Unknown |
| 14      | Men-ACWY                     | *Neisseria meningitidis* C | Yes |
| 15      | Men-ACWY                     | *N. meningitidis* Y | Yes |
| 16      | PCV-13                       | *Haemophilus influenzae* n.t | No |
| 17      | PCV-7, HiB                   | *H. influenzae* n.t | No |
| 18      | PPV-23                       | *H. influenzae* n.t | No |
| 19      | PPV-23                       | *H. influenzae* n.t | No |
| 20      | PPV-23, Men-C, Hib           | *H. influenzae* n.t | No |
| 21      | PPV-23                       | *Streptococcus mitis* | No |
| 22      | PPV-23                       | *S. mitis* | No |
| 23      | PPV-23                       | Negative culture | Unknown |
| 24      | PPV-23                       | Negative culture | Unknown |
| 25      | PCV-13, Men-C, Hib           | Group B streptococcus | No |
| 26      | PCV-23                       | Unknown pathogen b | Unknown |
| 27      | PPV-23, PCV-13, Men-ACWY     | Unknown pathogen b | Unknown |

Abbreviations: Hib, *H. influenzae* type b conjugate vaccine; Men-ACWY, group ACWY conjugate meningococcal vaccine; Men-C, group C conjugate meningococcal vaccine; Men-B, group B meningococcal vaccine; PCV-7, 7-valent pneumococcal conjugate vaccine; PCV-13, 13-valent pneumococcal conjugate vaccine; PPV-23, 23-valent pneumococcal polysaccharide vaccine.

* a No serotype or serogroup was retrieved.
* b No pathogen was retrieved.
meningitis due to the same serotype, 2 patients had recurrent nontypeable *H. influenzae* meningitis, and 1 patient had recurrent meningococcal meningitis due to the same serogroup (Supplementary Table 2).

**DISCUSSION**

Our study shows that recurrent meningitis occurs in 6% of episodes and mainly in those with predisposing factors such as CSF leakage, ear or sinus infections, and an immunosuppressive state. Predominant causative pathogens are *S. pneumoniae* and nontypeable, nontypeable *H. influenzae*. Disease course was less severe compared with nonrecurrent meningitis patients, leading to a lower case fatality rate.

No underlying risk factor was found in a substantial number of patients with recurrent meningitis (28%). Early identification of the predisposing factor may lead to prevention of new recurrences [4, 13–15]. The active search for predisposing factors should focus on anatomical defects and immunodeficiencies. CSF leaks can be identified with CSF markers (β-2 transferrin test and β-trace) and with cranial imaging techniques such as thin-slice computed tomography of the skull base and magnetic resonance imaging with 3-dimensional constructive interference in steady state. A primary or secondary immunodeficiency can be detected with a careful history and laboratory tests that include quantitative immunoglobulins, specific antibody levels, pre- and post-immunization antibody levels, IgG subclasses, and complement function [16–18]. Recurrent meningococcal meningitis is associated with complement deficiencies, with a recurrence risk of 45% [7, 14, 19]. In our study, 2 patients with a known complement deficiency were included, both with a recurrent meningococcal meningitis. The role of inborn errors of innate immunity in susceptibility of bacterial meningitis and recurrent meningitis, in particular, is unclear. Defects in the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) pathway and chemotaxis have been described to predispose to severe invasive pneumococcal disease, but the frequency and relevance in recurrent bacterial meningitis have not been systematically studied [20–22].

Patients with recurrent bacterial meningitis have a more favorable outcome compared with nonrecurrent meningitis patients. This is in line with previous results of smaller studies [3, 4]. Although speculative, the favorable disease outcome in recurrent meningitis patients can be explained by several factors. First, patients with recurrent meningitis might recognize symptoms of meningitis, promoting early medical attention. Patients with recurrent meningitis presented early with less severe symptoms compared with the nonrecurrent cases. In a disease as deadly as bacterial meningitis, early antibiotic treatment is one of the most important factors for favorable outcome [23]. Second, patients with recurrent meningitis had a lower rate of bacteremia and systemic complications [24, 25]. Episodes are often predisposed by a CSF leakage, which contributes to a better prognosis due to the relatively benign pathophysiology [4]. Third, patients with recurrent meningitis might have a less severe inflammatory response, potentially caused by immunocompromise and inborn errors of innate immunity. Bacterial meningitis is a complex disease with outcomes driven by the host inflammatory response [23]. Patients with less severe inflammatory response might have better disease outcomes. Finally, a competing risk between mortality and recurrence of illness has been described that might explain the favorable outcome, as there is no recurrence of meningitis when a patient has died [3]. The outcome of recurrent meningitis episodes appears to be favorable; however, we have identified a large number of patients with long-term neurological sequelae such as cognitive deficits after bacterial meningitis (32%). This provides further incentive to actively search for underlying conditions to prevent further recurrent episodes [2, 26].

Recurrent meningitis episodes were predominantly caused by *S. pneumoniae* and *H. influenzae*, and we found recurrent meningitis patients to have multiple recurrent episodes due to different pathogens. We found that less than one-third of the patients received vaccination. The benefit of vaccination is uncertain because controlled studies on the effect of vaccination in recurrent meningitis patients are not available, the available vaccines only cover 39% of the bacterial strains that cause recurrent meningitis, and vaccination failures occur [7, 8]. On the other hand, vaccination is minimally invasive, the risk for adverse events is low, and, according to expert opinion, vaccination is indicated in these high-risk patients. Therefore, we do recommend the use of Hib, PPV-23, meningococcal serogroup ACYW, and meningococcal serogroup B after a second bacterial meningitis episode or directly after a first episode in those with a specific risk factor (eg, CSF leak) [4, 27, 28].

There are several limitations to this study. First, this was a prospective observational study with data collected via a CRF and additional data retrospectively collected through discharge letters. For some patients, specific information, such as predisposing factor, number of recurrent episodes, use of prophylactic antibiotics, and vaccination status, was not described in discharge letters and thus registered as unknown, which might have led to a less accurate description of patients’ characteristics. Second, some patients were referred to the outpatient clinic for ancillary diagnostics to identify a predisposing factor; unfortunately, no follow-up data could be retrieved. Therefore, underlying conditions predisposing for recurrent meningitis may have been missed. Finally, patients with a positive CSF culture were identified by the NRLBM. This resulted in only a small number of included patients with a negative CSF culture. Negative CSF cultures have been reported to occur in 11%–41% of patients clinically suspected for bacterial meningitis, and this may be more common in recurrent meningitis episodes [3, 28, 29]. Nonetheless, this large nationwide study allowed us to describe a representative group of patients with recurrent community-acquired bacterial meningitis episodes.
In conclusion, recurrent meningitis frequently occurs due to predisposing factors, most commonly ear or sinus infections and CSF leakage. The disease course is more favorable with a lower mortality rate compared with nonrecurrent meningitis patients. Recurrent episodes are predominantly caused by *S. pneumoniae* and *H. influenzae*, and these patients can have multiple recurrent episodes due to different pathogens. We recommend actively searching for a predisposing factor after a second episode of bacterial meningitis and vaccination after a first episode of *S. pneumoniae*, *N. meningitidis*, or *H. influenzae* meningitis; a second episode; or in case of an identified predisposing factor.

**Supplementary Data**

Supplementary materials are available at *Clinical Infectious Diseases* online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.

**Notes**

*Financial support.* This work was supported by the Netherlands Organization for Health Research and Development (ZonMw; NWO-Vidi grant 917.17.308 to M. B. and NWO-Vici grant 918.19.627 to D. B.), the Academic Medical Center (AMC Fellowship to D. B.), and the European Research Council (starting grant to D. B.). The Netherlands Reference Laboratory for Bacterial Meningitis is supported by the National Institute of Public Health and the Environmental Protection, Bilthoven. A. v. d. E. reports a grant from Pfizer (IRRI 7173197), consulting fees paid to the institution from GSK, and science advisory board participation with Pfizer outside the submitted work.

*Potential conflicts of interest.* All authors: No reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

**References**

1. Bijlsma MW, Brouwer MC, Kasanmoentalib ES, et al. Community-acquired bacterial meningitis in adults in the Netherlands, 2006–14: a prospective cohort study. Lancet Infect Dis 2016; 16:339–47.
2. Lucas MJ, Brouwer MC, van de Beek D. Neurological sequelae of bacterial meningitis. Neth J Med 2008; 70:2256–61.
3. van de Beek D, Brouwer MC, Spanjaard L, van Gans J, van der Poll T. Community-acquired meningitis. Clin Microbiol Infect 2005; 11:1147–52.
4. Ter Horst J, Brouwer MC, van der Ende A, van de Beek D. Recurrent bacterial meningitis in adults with cerebrospinal fluid leakage. Clin Infect Dis 2020; 70:2256–61.
5. Tebruegge M, Curtis N. Epidemiology, etiology, pathogenesis, and diagnosis of recurrent bacterial meningitis. Clin Microbiol Rev 2008; 21:519–37.
6. Adriani KS, Brouwer MC, van de Beek D. Risk factors for community-acquired bacterial meningitis in adults. Neth J Med 2015; 73:53–60.
7. Figueiredo AHA, Brouwer MG, van de Beek D. Acute community-acquired bacterial meningitis. Neurol Clin 2018; 36:809–20.
8. Koelman DLH, Brouwer MC, van de Beek D. Resurgence of pneumococcal meningitis in Europe and Northern America. Clin Microbiol Infect 2020; 26:199–204.
9. van de Beek D, Cabellos C, Dzupova O, et al. ESCMID guideline: diagnosis and treatment of acute bacterial meningitis. Clin Microbiol Infect 2016; 22(Suppl 3):S37–62.
10. Spanos A, Harrell FE Jr, Durack DT. Differential diagnosis of acute meningitis. An analysis of the predictive value of initial observations. JAMA 1989; 262:2700–7.
11. Austrian R. The quellung reaction, a neglected microbiologic technique. Mt Sinai J Med 1976; 43:699–709.
12. Slaterus KW. Serological typing of meningococci by means of micro–precipitation. Antonie Van Leeuwenhoek 1961; 27:305–15.
13. Verma N, Savy LE, Lund VJ, Cropley I, Chee R, Seneviratne SL. An important diagnosis to consider in recurrent meningitis. JRSM Short Rep 2013; 4:204253313488640.
14. Brouwer MC, de Gans J, Heckenberg SG, Koedel U, Whitney CG, Wijdicks E. Host genetic susceptibility to pneumococcal and meningococcal disease: a systematic review and meta-analysis. Lancet Infect Dis 2009; 9:31–44.
15. Adriani KS, Brouwer MC, Geldhoff M, et al. Common polymorphisms in the complement system and susceptibility to bacterial meningitis. J Infect 2013; 66:255–62.
16. Oakley GM, Ali JA, Schlosser RJ, Harvey RJ, Orlandi RR. Diagnosis of cerebrospinal fluid rhinorrhea: an evidence-based review with recommendations. Int Forum Allergy Rhinol 2016; 6:8–16.
17. Algin O, Hakyemez B, Gokalp G, Ozcan T, Korfali E, Parlak M. The contribution of 3D-CISS and contrast-enhanced MR cisternography in detecting cerebrospinal fluid leak in patients with rhinorrhea. Br J Radiol 2010; 83:225–32.
18. Iaoa B, Oliveira TAE. Laboratory evaluation of primary immunodeficiencies. J Allergy Clin Immunol 2009; 125:9.
19. Swart AG, Fijen CA, te Bulte MT, Daha MR, Dankert J, Kuiper EJ. Complement deficiencies and meningococcal disease in The Netherlands. Ned Tijdschr Geneeskd 1993; 137:1147–52.
20. Picard C, Puel A, Bustamante J, Ku CL, Casanova JL. Primary immunodeficiencies associated with pneumococcal disease. Curr Opin Allergy Clin Immunol 2003; 3:451–9.
21. Mook-Kanamori BB, Geldhoff M, van der Poll T, van de Beek D. Pathogenesis and pathophysiology of pneumococcal meningitis. Clin Microbiol Rev 2011; 24:557–91.
22. Jones MR, Simms BT, Lupa MM, Kogan MS, Mizgerd JP. Lung NF-kappaB activation and pathophysiology of pneumococcal meningitis. Clin Microbiol Infect 2016; 22(Suppl 3):S37–62.
23. van de Beek D, Brouwer M, Hasbun R, Koebed U, Whitney CG, Wijdicks E. Community-acquired bacterial meningitis. Nat Rev Dis Primers 2016; 2:16074.
24. Figueiredo AHA, Brouwer MC, Bijlsma MW, van der Ende A, van de Beek D. Community-acquired pneumonia in patients with bacterial meningitis: a prospective nationwide cohort study. Clin Microbiol Infect 2020; 26:513.e7–513.e11.
25. Weissfelt M, van de Beek D, Spanjaard L, Reitsma JB, de Gans J. Attenuated cerebrospinal fluid leukocyte count and sepsis in adults with pneumococcal meningitis: a prospective cohort study. BMC Infect Dis 2006; 6:149.
26. Kloek AT, Brouwer MC, Schmand B, Tanck MWT, van de Beek D. Long-term neurologic and cognitive outcome and quality of life in adults after pneumococcal meningitis. Clin Microbiol Infect 2020; 26:1361–7.
27. McIntyre PB, O’Brien KL, Greenwood B, van de Beek D. Effect of vaccines on bacterial meningitis worldwide. Lancet 2012; 380:1703–11.
28. Brouwer MC, Tunkel AR, van de Beek D. Epidemiology, diagnosis, and antimicrobial treatment of acute bacterial meningitis. Clin Microbiol Rev 2010; 23:467–92.
29. van de Beek D, Drake JM, Tunkel AR. Nosocomial bacterial meningitis. N Engl J Med 2010; 362:146–54.